Obesity's Impact on Atrial Fibrillation Ablation: Insights from CABANA | Retatrutide News

The CABANA trial examines obesity's role in atrial fibrillation ablation outcomes. The implications for Retatrutide and GLP-1 agonists remain unclear fr...
Clinical Trials · October 30, 2026